In This Article:
Release Date: May 07, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Amarin Corp PLC (NASDAQ:AMRN) has extended its European IP protection to 2039, providing a longer runway for maximizing product value.
-
The company has expanded its global presence, launching VESCEPA in 21 countries, up from 7 in 2023.
-
Amarin Corp PLC (NASDAQ:AMRN) has maintained a debt-free balance sheet while efficiently managing cash over 10 consecutive quarters.
-
The company has achieved regulatory and early commercial success in various regions, including Southeast Asia, MENA, and Australia.
-
Amarin Corp PLC (NASDAQ:AMRN) has made significant progress in Europe, with VESCEPA revenues growing by 16% sequentially, driven by demand in Spain, the UK, and Central Eastern Europe.
Negative Points
-
Total net revenue for the first quarter of 2025 was $42 million, a decline from $56.5 million in the first quarter of 2024.
-
US product revenue decreased to $35.7 million from $48.1 million in the first quarter of 2024 due to generic competition and decreased volume.
-
The company reported a net loss of $15.7 million for the first quarter of 2025, compared to a net loss of $10 million in the prior year period.
-
Rest of the world revenues were less than $0.1 million, showing a significant decline year over year and sequentially.
-
Amarin Corp PLC (NASDAQ:AMRN) anticipates year-over-year declines in the US market due to market dynamics and generic competition.
Q & A Highlights
Q: Rest of world revenues fell significantly year over year and sequentially. What drove this decline, and should we expect it to bounce back up going forward? A: The decline in rest of world revenues is due to the variability in how individual countries report, making quarterly revenue choppy as we are in the early stages of launching in many markets. Despite limited revenues for Q1, we are encouraged by the in-market demand and expect growth as we continue to build a foundation in these countries. The variability is expected to continue, but overall, we are optimistic about future growth.
Q: Given the established data on cardiovascular outcomes, what additional real-world evidence or clinical development plans do you have to potentially expand labeling or strengthen differentiation against generics? A: We are actively generating new data to differentiate our product, focusing on the uniqueness of IPE. We have hundreds of publications showing its value, and we continue to support data from external collaborators. Our efforts have led to over 50 guideline recommendations globally, reinforcing the scientific foundation and uniqueness of our product. We remain committed to generating new data to show the product's potential in reducing cardiovascular risk.